Security
Monte Rosa Therapeutics, Inc. Common Stock · GLUE
GLUENASDAQCommon stockCurrentCIK 1826457Updated Oct 7, 2026
Name history
Monte Rosa Therapeutics, Inc. · through Oct 6, 2026
GLUE price & chart
Loading TradingView…
NASDAQ:GLUE on TradingView ↗About the company
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G - filed by Vestal Point Capital, LP regarding Monte Rosa Therapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 459,841,000Source | 315,080,000Source | 691,161,000Source | 359,586,000Source | 344,114,000Source | 736,428,000Source | 393,199,000Source | 266,746,000Source | 448,659,000Source | 438,732,000Source | 303,755,000Source | 342,389,000Source |
| Property, Plant and Equipment, NetUSD | 27,598,000Source | 31,442,000Source | 29,932,000Source | 29,052,000Source | 33,250,000Source | 28,409,000Source | 29,336,000Source | 34,036,000Source | 25,986,000Source | 29,483,000Source | 33,803,000Source | 27,075,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 208,343,000Source | 125,575,000Source | 90,104,000Source | 69,429,000Source | 108,847,000Source | 159,859,000Source | 78,530,000Source | 99,752,000Source | 129,883,000Source | 224,254,000Source | 128,101,000Source | 54,912,000Source |
| Assets, CurrentUSD | 401,817,000Source | 251,207,000Source | 631,406,000Source | 299,465,000Source | 277,896,000Source | 677,547,000Source | 332,280,000Source | 199,036,000Source | 393,185,000Source | 377,440,000Source | 236,212,000Source | 275,886,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,594,000Source | 8,426,000Source | 5,382,000Source | 6,501,000Source | 5,849,000Source | 6,718,000Source | 4,798,000Source | 5,543,000Source | 4,481,000Source | 5,118,000Source | 3,294,000Source | 4,444,000Source |
| Operating Lease, Right-of-Use AssetUSD | 25,065,000Source | 27,364,000Source | 24,056,000Source | 25,674,000Source | 27,893,000Source | 24,693,000Source | 26,263,000Source | 28,422,000Source | 24,386,000Source | 26,831,000Source | 28,808,000Source | 34,832,000Source |
| Other Assets, NoncurrentUSD | 411,000Source | 159,000Source | 828,000Source | 445,000Source | 209,000Source | 832,000Source | 440,000Source | 389,000Source | 148,000Source | 115,000Source | 352,000Source | 278,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 214,004,000Source | 109,623,000Source | 203,880,000Source | 91,506,000Source | 119,443,000Source | 214,512,000Source | 118,039,000Source | 114,227,000Source | 215,603,000Source | 215,796,000Source | 124,505,000Source | 70,976,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 9,000Source | 6,000Source | 6,000Source | 8,000Source | 6,000Source | 5,000Source | 7,000Source | 6,000Source | 5,000Source | 5,000Source |
| Retained Earnings (Accumulated Deficit)USD | -431,079,000Source | -452,025,000Source | -565,114,000Source | -403,998,000Source | -428,166,000Source | -521,717,000Source | -391,703,000Source | -397,856,000Source | -477,214,000Source | -438,588,000Source | -365,888,000Source | -230,536,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -3,247,000Source | -2,322,000Source | -5,165,000Source | -3,373,000Source | -2,670,000Source | -4,746,000Source | -3,329,000Source | -2,693,000Source | -3,827,000Source | -3,356,000Source | -2,724,000Source | -1,752,000Source |
| Stockholders' Equity Attributable to ParentUSD | 245,837,000Source | 205,457,000Source | 487,281,000Source | 268,080,000Source | 224,671,000Source | 521,916,000Source | 275,160,000Source | 152,519,000Source | 233,056,000Source | 222,936,000Source | 179,250,000Source | 271,413,000Source |
| Additional Paid in Capital, Common StockUSD | 680,157,000Source | 659,798,000Source | 1,057,551,000Source | 675,445,000Source | 655,501,000Source | 1,048,371,000Source | 670,186,000Source | 553,063,000Source | 714,090,000Source | 664,874,000Source | 547,857,000Source | 503,696,000Source |
| Liabilities and EquityUSD | 459,841,000Source | 315,080,000Source | 691,161,000Source | 359,586,000Source | 344,114,000Source | 736,428,000Source | 393,199,000Source | 266,746,000Source | 448,659,000Source | 438,732,000Source | 303,755,000Source | 342,389,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 61,443,000Source | 41,641,000Source | 59,658,000Source | 41,852,000Source | 42,348,000Source | 71,036,000Source | 59,216,000Source | 41,293,000Source | 64,212,000Source | 156,946,000Source | 46,592,000Source | 25,569,000Source |
| Operating Lease, Liability, CurrentUSD | 4,241,000Source | 3,646,000Source | 4,630,000Source | 4,094,000Source | 3,471,000Source | 4,483,000Source | 3,865,000Source | 3,345,000Source | 4,397,000Source | 3,714,000Source | 3,162,000Source | 3,127,000Source |
| Accounts Payable, CurrentUSD | 14,509,000Source | 3,978,000Source | 7,152,000Source | 5,581,000Source | 6,473,000Source | 7,900,000Source | 6,489,000Source | 6,828,000Source | 3,550,000Source | 17,215,000Source | 11,152,000Source | 7,862,000Source |
| Operating Lease, Liability, NoncurrentUSD | 35,927,000Source | 40,052,000Source | 33,357,000Source | 37,037,000Source | 40,885,000Source | 34,581,000Source | 37,999,000Source | 41,837,000Source | 34,794,000Source | 39,001,000Source | 42,877,000Source | 43,874,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | 25,773,000Source | — | — | 25,594,000Source | — | — | 26,694,000Source | — | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 391,300,000Source | — | 621,100,000Source | 290,600,000Source | — | 666,200,000Source | — | — | 377,100,000Source | — | — | — |
| Deferred Revenue, CurrentUSD | 24,791,000Source | 18,918,000Source | 22,103,000Source | 18,410,000Source | 19,645,000Source | 33,059,000Source | 32,575,000Source | 20,407,000Source | 29,571,000Source | 117,232,000Source | 17,678,000Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | — | — | —Source | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -44,503,000Source | 46,885,000Source | -38,626,000Source | -72,700,000Source | -135,352,000Source | -108,501,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,949,000Source | 5,298,000Source | 18,865,000Source | 18,126,000Source | 16,669,000Source | 11,664,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 4,377,000Source | -10,874,000Source | -13,708,000Source | 6,252,000Source | 5,758,000Source | -744,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -37,369,000Source | -45,492,000Source | -22,798,000Source | 41,996,000Source | -43,802,000Source | -92,466,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -260,997,000Source | -100,229,000Source | -101,833,000Source | -44,452,000Source | 88,801,000Source | -219,219,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,868,000Source | 1,587,000Source | 4,700,000Source | 3,988,000Source | 19,041,000Source | 12,911,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 328,335,000Source | 14,000Source | 30,351,000Source | 98,892,000Source | 27,492,000Source | 20,466,000Source |
| Dividends paid | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 29,969,000Source | -145,707,000Source | -94,280,000Source | 96,436,000Source | 72,491,000Source | -291,219,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 213,293,000Source | 130,483,000Source | 95,043,000Source | 74,379,000Source | 164,806,000Source | 83,410,000Source | 134,837,000Source | 229,117,000Source | 132,681,000Source | 60,190,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 5,179,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,364,000Source | 4,282,000Source | 5,970,000Source | 4,894,000Source | 5,949,000Source | 5,298,000Source | 18,865,000Source | 18,126,000Source | 16,669,000Source | 11,664,000Source |
| Amortization of Intangible AssetsUSD | — | — | 637,000Source | 578,000Source | 708,000Source | 615,000Source | 643,000Source | 574,000Source | 2,500,000Source | — | 2,500,000Source | 3,300,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 391,300,000Source | — | 621,100,000Source | 290,600,000Source | 666,200,000Source | — | 377,100,000Source | — | — | — |
| DepreciationUSD | — | — | 2,095,000Source | 2,103,000Source | 1,911,000Source | 2,125,000Source | 2,029,000Source | 2,048,000Source | 8,356,000Source | 8,121,000Source | 6,222,000Source | 3,745,000Source |
| Dividends PayableUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -29,000Source | -153,000Source | 25,000Source | 1,390,000Source | -8,000Source | 173,000Source | 1,484,000Source | 416,000Source | -930,000Source | 10,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 59,000Source | 59,000Source | 0Source | 24,000Source | 109,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 0Source | 59,000Source | 59,000Source | 0Source | 24,000Source | 109,000Source |
| General and Administrative ExpenseUSD | — | — | 9,065,000Source | 8,127,000Source | 10,134,000Source | 8,095,000Source | 10,175,000Source | 8,703,000Source | 36,380,000Source | 35,171,000Source | 32,039,000Source | 27,323,000Source |
| Income Tax Expense (Benefit)USD | — | — | -3,177,000Source | 71,000Source | 208,000Source | 1,199,000Source | 52,000Source | 822,000Source | -1,097,000Source | 2,570,000Source | 338,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -27,081,000Source | -23,859,000Source | -43,397,000Source | -12,295,000Source | -44,503,000Source | 46,885,000Source | -38,626,000Source | -72,700,000Source | -135,352,000Source | -108,501,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,717,000Source | 2,739,000Source | 5,941,000Source | 4,458,000Source | 5,583,000Source | 3,671,000Source | 14,485,000Source | 10,982,000Source | 8,297,000Source | 3,883,000Source |
| Operating ExpensesUSD | — | — | 45,743,000Source | 35,743,000Source | 58,098,000Source | 38,748,000Source | 54,244,000Source | 40,893,000Source | 177,880,000Source | 156,734,000Source | 143,311,000Source | 112,384,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 20,055,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 4,522,000Source | 14,000Source | 5,723,000Source | 1,061,000Source | 2,030,000Source | 439,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 12,768,000Source | 9,216,000Source | 8,968,000Source | 23,194,000Source | 4,210,000Source | 84,929,000Source | 123,672,000Source | 75,622,000Source | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | — | —Source | — | — | — | — |
| Pension Cost (Reversal of Cost) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -32,975,000Source | -26,527,000Source | -49,130,000Source | -15,554,000Source | -50,034,000Source | 44,036,000Source | -54,208,000Source | -81,112,000Source | -143,311,000Source | -112,384,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -30,258,000Source | -23,788,000Source | -43,189,000Source | -11,096,000Source | -44,451,000Source | 47,707,000Source | -39,723,000Source | -70,130,000Source | -135,014,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | -3,177,000Source | 71,000Source | 208,000Source | 1,199,000Source | 52,000Source | 822,000Source | -1,097,000Source | 2,570,000Source | 338,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -27,081,000Source | -23,859,000Source | -43,397,000Source | -12,295,000Source | -44,503,000Source | 46,885,000Source | -38,626,000Source | -72,700,000Source | -135,352,000Source | -108,501,000Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 82,397,753Source | 82,011,670Source | 101,478,945Source | 82,186,768Source | 99,883,878Source | 82,148,719Source | 83,071,185Source | 73,910,026Source | 51,396,961Source | 47,227,370Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 82,397,753Source | 82,011,670Source | 101,478,945Source | 82,186,768Source | 99,883,878Source | 82,956,423Source | 83,071,185Source | 73,910,026Source | 51,396,961Source | 47,227,370Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 637,000Source | 578,000Source | 708,000Source | 615,000Source | 643,000Source | 574,000Source | 2,500,000Source | — | 2,500,000Source | 3,300,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -29,000Source | -153,000Source | 25,000Source | 1,390,000Source | -8,000Source | 173,000Source | 1,484,000Source | 416,000Source | -930,000Source | 10,000Source |
| General and Administrative ExpenseUSD | — | — | 9,065,000Source | 8,127,000Source | 10,134,000Source | 8,095,000Source | 10,175,000Source | 8,703,000Source | 36,380,000Source | 35,171,000Source | 32,039,000Source | 27,323,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -23,077,000Source | -20,708,000Source | -19,543,000Source | -17,232,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.33Source | -0.29Source | -0.43Source | -0.15Source | -0.45Source | 0.57Source | -0.46Source | -0.98Source | -2.63Source | -2.3Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | -0.33Source | -0.29Source | -0.43Source | -0.15Source | -0.45Source | 0.57Source | -0.46Source | -0.98Source | -2.63Source | -2.3Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 2,746,000Source | 2,892,000Source | 5,916,000Source | 3,068,000Source | 5,591,000Source | 3,439,000Source | 12,942,000Source | 10,566,000Source | 9,334,000Source | 3,764,000Source |
| Labor and Related ExpenseUSD | — | — | 5,696,000Source | 5,702,000Source | — | 5,479,000Source | 13,493,000Source | 11,352,000Source | — | 22,153,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 2,717,000Source | 2,739,000Source | 5,941,000Source | 4,458,000Source | 5,583,000Source | 3,671,000Source | 14,485,000Source | 10,982,000Source | 8,297,000Source | 3,883,000Source |
| Operating ExpensesUSD | — | — | 45,743,000Source | 35,743,000Source | 58,098,000Source | 38,748,000Source | 54,244,000Source | 40,893,000Source | 177,880,000Source | 156,734,000Source | 143,311,000Source | 112,384,000Source |
| Other General and Administrative ExpenseUSD | — | — | 8,574,000Source | 7,455,000Source | — | 7,850,000Source | 10,111,000Source | 8,228,000Source | 33,867,000Source | 29,631,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 36,678,000Source | 27,616,000Source | 47,964,000Source | 30,653,000Source | 44,069,000Source | 32,190,000Source | 141,500,000Source | 121,563,000Source | 111,272,000Source | 85,061,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 12,768,000Source | 9,216,000Source | 8,968,000Source | 23,194,000Source | 4,210,000Source | 84,929,000Source | 123,672,000Source | 75,622,000Source | — | — |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | — | —Source | — | — | — | — |
Filing attachments
glue-ex99_1.htm · 8-K · 2026-10-01
Exhibit 99.1 Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammat…
Read attachment ↗glue-ex99_2.htm · 8-K · 2026-10-01
Degrading Proteins, Making Medicines MRT-8102 GFORCE-1 Clinical Study Results October 1, 2026 Exhibit 99.2 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “woul…
Read attachment ↗glue-ex99_1.htm · 8-K · 2026-09-08
EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 c…
Read attachment ↗glue-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk and cardiometabolic syndrome in H2 2026, in patients with gout flar…
Read attachment ↗glue-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated athero…
Read attachment ↗glue-ex99_1.htm · 8-K · 2026-03-17
EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerabil…
Read attachment ↗